This is such a great explanation:
"Developers of PRO 140 chose a different path than all the other drug developers. Instead of treating the primary tumor and measuring tumor reduction, they sought to control the mechanism that eventually kills the cancer patient - metastasis. It accounts for 90% of cancer patient deaths, versus death from the primary tumor. When a tumor sheds clusters of cancer cells, called Circulating Tumor Cells (CTCs), they typically have 1-3 hours to find a home or else the immune system destroys them. In its first two patients in the phase 1b/2 TNBC clinical trial, PRO 140 eliminated all the CTCs that would be responsible for metastasis. This is a major breakthrough in treating all metastatic disease because all cancers use the same pathways regardless of the disease type."
"Developers of PRO 140 chose a different path than all the other drug developers. Instead of treating the primary tumor and measuring tumor reduction, they sought to control the mechanism that eventually kills the cancer patient - metastasis. It accounts for 90% of cancer patient deaths, versus death from the primary tumor. When a tumor sheds clusters of cancer cells, called Circulating Tumor Cells (CTCs), they typically have 1-3 hours to find a home or else the immune system destroys them. In its first two patients in the phase 1b/2 TNBC clinical trial, PRO 140 eliminated all the CTCs that would be responsible for metastasis. This is a major breakthrough in treating all metastatic disease because all cancers use the same pathways regardless of the disease type."
4
